Searle Celebrex Rxs Climb 5%; Merck Dental Work Bolsters Vioxx New Rxs
Celebrex refills are helping Searle weather a 10% downturn in new scripts in the third quarter and to maintain the COX-2 inhibitor's position in the valuable chronic use market, Searle CEO Alan Heller said during an Oct. 27 presentation to the CIBC World Markets Health Care Conference in New York City.
You may also be interested in...
Nearly half of new Vioxx (refecoxib) scripts are for newly-diagnosed osteoarthritis patients or patients switching to a prescription medication from an over-the-counter treatment, Merck Investor Relations Director Laura Jordan said during a second quarter earnings teleconference July 23.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials